{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:55:22Z","timestamp":1786985722125,"version":"build-2736575974"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T00:00:00Z","timestamp":1752192000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002996","name":"Hartstichting","doi-asserted-by":"publisher","award":["03-007-2023-0068"],"award-info":[{"award-number":["03-007-2023-0068"]}],"id":[{"id":"10.13039\/501100002996","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016405","name":"European Atherosclerosis Society","doi-asserted-by":"publisher","award":["2023"],"award-info":[{"award-number":["2023"]}],"id":[{"id":"10.13039\/100016405","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004320","name":"Philips","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004320","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001634","name":"University of Galway","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001634","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cardiovascular Revascularization Medicine"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.carrev.2025.07.003","type":"journal-article","created":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T02:40:59Z","timestamp":1751942459000},"page":"67-77","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Impact of elevated lipoprotein(a) on epicardial coronary flow conductance and endoluminal atherosclerotic disease distribution"],"prefix":"10.1016","volume":"86","author":[{"given":"Mick P.L.","family":"Renkens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsung-Ying","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pruthvi C.","family":"Revaiah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigetaka","family":"Kageyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan H.C.","family":"Reiber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robbert J.","family":"de Winter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maik","family":"Grundeken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick S.","family":"Nurmohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Stroes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scot","family":"Garg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens","family":"von Birgelen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sjoerd","family":"Hofma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Alkhalil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liesbeth","family":"Rosseel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faisal","family":"Sharif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter C.","family":"Smits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Baumbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinobu","family":"Onuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna J.","family":"Wykrzykowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick W.","family":"Serruys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.carrev.2025.07.003_bb0005","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.atherosclerosis.2019.10.011","article-title":"HEART UK consensus statement on lipoprotein(a): a call to action","volume":"291","author":"Cegla","year":"2019","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.carrev.2025.07.003_bb0010","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s10557-016-6648-3","article-title":"Human genetics and the causal role of lipoprotein(a) for various diseases","volume":"30","author":"Kronenberg","year":"2016","journal-title":"Cardiovasc Drugs Ther"},{"issue":"4","key":"10.1016\/j.carrev.2025.07.003_bb0015","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jama.2009.1063","article-title":"Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality","volume":"302","author":"Erqou","year":"2009","journal-title":"JAMA"},{"issue":"39","key":"10.1016\/j.carrev.2025.07.003_bb0020","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement","volume":"43","author":"Kronenberg","year":"2022","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.carrev.2025.07.003_bb0025","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.jacl.2023.05.094","article-title":"Association between lipoprotein(a) and long-term outcomes after percutaneous coronary intervention for lesions with in-stent restenosis","volume":"17","author":"Zhang","year":"2023","journal-title":"J Clin Lipidol"},{"issue":"2","key":"10.1016\/j.carrev.2025.07.003_bb0030","first-page":"275","article-title":"Lipoprotein (a) is related to in-stent neoatherosclerosis incidence rate and plaque vulnerability: Optical Coherence Tomography Study","volume":"39","author":"Yuan","year":"2023","journal-title":"Int J Card Imaging"},{"key":"10.1016\/j.carrev.2025.07.003_bb0035","doi-asserted-by":"crossref","unstructured":"Szarek M, Reijnders E, Jukema JW, et al. Relating lipoprotein(a) concentrations to cardiovascular event risk after acute coronary syndrome: a comparison of three tests. Circulation;0(0). DOI: doi:https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.123.066398.","DOI":"10.1161\/CIRCULATIONAHA.123.066398"},{"issue":"22","key":"10.1016\/j.carrev.2025.07.003_bb0040","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1001\/jama.2009.801","article-title":"Genetically elevated lipoprotein(a) and increased risk of myocardial infarction","volume":"301","author":"Kamstrup","year":"2009","journal-title":"JAMA"},{"issue":"23","key":"10.1016\/j.carrev.2025.07.003_bb0045","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","article-title":"Lipoprotein(a) as a cardiovascular risk factor: current status","volume":"31","author":"Nordestgaard","year":"2010","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.carrev.2025.07.003_bb0050","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1161\/ATVBAHA.120.315291","article-title":"Lp(a) (lipoprotein[a]) concentrations and incident atherosclerotic cardiovascular disease: new insights from a large national biobank","volume":"41","author":"Patel","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"10.1016\/j.carrev.2025.07.003_bb0055","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jacc.2021.10.044","article-title":"Association of lipoprotein(a) with atherosclerotic plaque progression","volume":"79","author":"Kaiser","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.carrev.2025.07.003_bb0060","doi-asserted-by":"crossref","DOI":"10.1001\/jamacardio.2024.1874","article-title":"Lipoprotein(a) and long-term plaque progression, low-density plaque, and pericoronary inflammation","author":"Nurmohamed","year":"2024","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.carrev.2025.07.003_bb0065","first-page":"101120","article-title":"Lipoprotein (a) levels and vulnerable characteristics in nonculprit plaque in patients with acute coronary syndrome","volume":"43","author":"Kato","year":"2022","journal-title":"Int J Cardiol Heart Vasc"},{"issue":"18","key":"10.1016\/j.carrev.2025.07.003_bb0070","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1016\/j.jacc.2023.02.050","article-title":"Lipoprotein(a), oxidized phospholipids, and coronary artery disease severity and outcomes","volume":"81","author":"Gilliland","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.carrev.2025.07.003_bb0075","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2147\/VHRM.S394134","article-title":"Elevated Lp(a) levels correlate with severe and multiple coronary artery stenotic lesions","volume":"19","author":"Al Hageh","year":"2023","journal-title":"Vasc Health Risk Manag"},{"issue":"1","key":"10.1016\/j.carrev.2025.07.003_bb0080","doi-asserted-by":"crossref","first-page":"12","DOI":"10.4103\/1995-705X.107114","article-title":"Lipoprotein (a) levels in relation to severity of coronary artery disease in North Indian patients","volume":"14","author":"Ashfaq","year":"2013","journal-title":"Heart Views"},{"issue":"36","key":"10.1016\/j.carrev.2025.07.003_bb0085","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","volume":"45","author":"Vrints","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.carrev.2025.07.003_bb0090","doi-asserted-by":"crossref","unstructured":"Hara H, Serruys PW, O'Leary N, et al. Angiography-derived physiology guidance vs usual care in an All-comers PCI population treated with the healing-targeted supreme stent and Ticagrelor monotherapy: PIONEER IV trial design. Am Heart J 2022;246:32\u201343. (in Eng). DOI: https:\/\/doi.org\/10.1016\/j.ahj.2021.12.018.","DOI":"10.1016\/j.ahj.2021.12.018"},{"issue":"3","key":"10.1016\/j.carrev.2025.07.003_bb0095","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","article-title":"2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes","volume":"41","author":"Knuuti","year":"2020","journal-title":"Eur Heart J"},{"issue":"38","key":"10.1016\/j.carrev.2025.07.003_bb0100","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC Guidelines for the management of acute coronary syndromes","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.carrev.2025.07.003_bb0105","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.atherosclerosis.2019.08.015","article-title":"Comparison of lipoprotein (a) serum concentrations measured by six commercially available immunoassays","volume":"289","author":"Scharnagl","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.carrev.2025.07.003_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2021.100053","article-title":"Novel method for quantification of lipoprotein (a)-cholesterol: implications for improving accuracy of LDL-C measurements","volume":"62","author":"Yeang","year":"2021","journal-title":"J Lipid Res"},{"issue":"19","key":"10.1016\/j.carrev.2025.07.003_bb0115","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1016\/j.jcin.2016.07.013","article-title":"Diagnostic accuracy of fast computational approaches to derive fractional flow reserve from diagnostic coronary angiography: the international multicenter FAVOR pilot study","volume":"9","author":"Tu","year":"2016","journal-title":"JACC Cardiovasc Interv"},{"issue":"2","key":"10.1016\/j.carrev.2025.07.003_bb0120","doi-asserted-by":"crossref","first-page":"180","DOI":"10.4244\/EIJ-D-18-00896","article-title":"Prognostic implication of three-vessel contrast-flow quantitative flow ratio in patients with stable coronary artery disease","volume":"15","author":"Hamaya","year":"2019","journal-title":"EuroIntervention"},{"issue":"7","key":"10.1016\/j.carrev.2025.07.003_bb0125","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.jcin.2014.03.004","article-title":"Fractional flow reserve calculation from 3-dimensional quantitative coronary angiography and TIMI frame count: a fast computer model to quantify the functional significance of moderately obstructed coronary arteries","volume":"7","author":"Tu","year":"2014","journal-title":"J Am Coll Cardiol Intv"},{"issue":"14","key":"10.1016\/j.carrev.2025.07.003_bb0130","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1016\/j.jcin.2023.04.026","article-title":"Anonymous comparison of various angiography-derived fractional flow reserve software with pressure-derived physiological assessment","volume":"16","author":"Ninomiya","year":"2023","journal-title":"J Am Coll Cardiol Intv"},{"issue":"22","key":"10.1016\/j.carrev.2025.07.003_bb0135","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1016\/j.jcin.2020.06.062","article-title":"Automated algorithm using pre-intervention fractional flow reserve pullback curve to predict post-intervention physiological results","volume":"13","author":"Lee","year":"2020","journal-title":"J Am Coll Cardiol Intv"},{"issue":"24","key":"10.1016\/j.carrev.2025.07.003_bb0140","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1016\/j.jcin.2022.09.048","article-title":"Differential improvement in angina and health-related quality of life after PCI in focal and diffuse coronary artery disease","volume":"15","author":"Collet","year":"2022","journal-title":"JACC Cardiovasc Interv"},{"issue":"14","key":"10.1016\/j.carrev.2025.07.003_bb0145","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","article-title":"2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation","volume":"42","author":"Collet","year":"2021","journal-title":"Eur Heart J"},{"issue":"14","key":"10.1016\/j.carrev.2025.07.003_bb0150","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1016\/j.jacc.2019.07.072","article-title":"Measurement of hyperemic pullback pressure gradients to characterize patterns of coronary atherosclerosis","volume":"74","author":"Collet","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.carrev.2025.07.003_bb0155","doi-asserted-by":"crossref","DOI":"10.1093\/eurjpc\/zwae007","article-title":"Impact of elevated lipoprotein(a) on coronary artery disease phenotype and severity","author":"Leistner","year":"2024","journal-title":"Eur J Prev Cardiol"},{"issue":"3","key":"10.1016\/j.carrev.2025.07.003_bb0160","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.jacc.2023.10.039","article-title":"Lipoprotein(a) is markedly more atherogenic than LDL","volume":"83","author":"Bj\u00f6rnson","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.carrev.2025.07.003_bb0165","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.atherosclerosis.2022.03.004","article-title":"Lipoprotein(a) levels from childhood to adulthood: data in nearly 3,000 children who visited a pediatric lipid clinic","volume":"349","author":"de Boer","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.carrev.2025.07.003_bb0170","doi-asserted-by":"crossref","unstructured":"Renkens MPL, Coerkamp CF, Witte LS, et al. Lipoprotein(a) in interventional cardiology: identifying patients at highest risk of recurrent cardiovascular events through early recognition \u2014 a case based review. Expert Rev Cardiovasc Ther 2024;22(8):353\u2013366. (in Eng). DOI: https:\/\/doi.org\/10.1080\/14779072.2024.2387678.","DOI":"10.1080\/14779072.2024.2387678"},{"key":"10.1016\/j.carrev.2025.07.003_bb0175","doi-asserted-by":"crossref","DOI":"10.4244\/EIJ-D-23-00516","article-title":"Preprocedural physiological assessment of coronary disease patterns to predict haemodynamic outcomes post-PCI","author":"Kotoku","year":"2023","journal-title":"EuroIntervention"},{"issue":"2","key":"10.1016\/j.carrev.2025.07.003_bb0180","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.atherosclerosis.2013.01.014","article-title":"Association between baseline lipoprotein (a) levels and restenosis after coronary stenting: meta-analysis of 9 cohort studies","volume":"227","author":"Qin","year":"2013","journal-title":"Atherosclerosis"},{"issue":"18","key":"10.1016\/j.carrev.2025.07.003_bb0185","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/j.jcin.2021.07.042","article-title":"Association of Lipoprotein(a) with recurrent ischemic events following percutaneous coronary intervention","volume":"14","author":"Yoon","year":"2021","journal-title":"JACC Cardiovasc Interv"},{"issue":"15","key":"10.1016\/j.carrev.2025.07.003_bb0190","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1093\/eurjpc\/zwae212","article-title":"Lipoprotein(a) and long-term in-stent restenosis after percutaneous coronary intervention","volume":"31","author":"Mahmoud","year":"2024","journal-title":"Eur J Prev Cardiol"},{"issue":"20","key":"10.1016\/j.carrev.2025.07.003_bb0195","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1056\/NEJMoa2211023","article-title":"Small interfering RNA to reduce lipoprotein(a) in cardiovascular disease","volume":"387","author":"O\u2019Donoghue","year":"2022","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.carrev.2025.07.003_bb0200","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1056\/NEJMoa1905239","article-title":"Lipoprotein(a) reduction in persons with cardiovascular disease","volume":"382","author":"Tsimikas","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.carrev.2025.07.003_bb0205","doi-asserted-by":"crossref","first-page":"100478","DOI":"10.1016\/j.ajpc.2023.100478","article-title":"Contemporary patterns of lipoprotein(a) testing and associated clinical care and outcomes","volume":"14","author":"Kelsey","year":"2023","journal-title":"Am J Prevent Cardiol"},{"key":"10.1016\/j.carrev.2025.07.003_bb0210","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1699-0463.1963.tb01808.x","article-title":"A new serum type system in man\u2014the LP system","volume":"59","author":"Berg","year":"1963","journal-title":"Acta Pathol Microbiol Scand"},{"issue":"1","key":"10.1016\/j.carrev.2025.07.003_bb0215","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European atherosclerosis society (EAS)","volume":"41","author":"Mach","year":"2019","journal-title":"Eur Heart J"},{"issue":"8","key":"10.1016\/j.carrev.2025.07.003_bb0220","first-page":"1129","article-title":"2021 Canadian cardiovascular society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults","volume":"37","author":"Pearson","year":"2021","journal-title":"Can J Cardiol"},{"issue":"18","key":"10.1016\/j.carrev.2025.07.003_bb0225","doi-asserted-by":"crossref","first-page":"e031255","DOI":"10.1161\/JAHA.123.031255","article-title":"Lipoprotein(a) testing trends in a large academic health system in the United States","volume":"12","author":"Bhatia","year":"2023","journal-title":"J Am Heart Assoc"},{"issue":"2","key":"10.1016\/j.carrev.2025.07.003_bb0230","article-title":"Lipoprotein(a) is a prevalent yet vastly underrecognized risk factor for cardiovascular disease","volume":"12","author":"Rendler","year":"2024","journal-title":"Health Care Curr Rev"},{"issue":"3","key":"10.1016\/j.carrev.2025.07.003_bb0235","doi-asserted-by":"crossref","first-page":"e477","DOI":"10.1016\/j.jacl.2024.02.004","article-title":"Lipoprotein(a) testing in lipid clinics across the UK: results of a national survey","volume":"18","author":"Ansari","year":"2024","journal-title":"J Clin Lipidol"},{"issue":"5","key":"10.1016\/j.carrev.2025.07.003_bb0240","doi-asserted-by":"crossref","first-page":"e873","DOI":"10.1016\/j.jacl.2024.07.012","article-title":"Attitudes and barriers to lipoprotein(a) testing: a survey of providers at the University of Pennsylvania Health System","volume":"18","author":"D\u2019Souza","year":"2024","journal-title":"J Clin Lipidol"},{"issue":"9","key":"10.1016\/j.carrev.2025.07.003_bb0245","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.jacc.2014.03.061","article-title":"Discrimination and net reclassification of cardiovascular risk with lipoprotein(a): prospective 15-year outcomes in the Bruneck Study","volume":"64","author":"Willeit","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.carrev.2025.07.003_bb0250","author":"Ference"},{"issue":"8","key":"10.1016\/j.carrev.2025.07.003_bb0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2022.100239","article-title":"Development and validation of an isoform-independent monoclonal antibody-based ELISA for measurement of lipoprotein(a)","volume":"63","author":"Marcovina","year":"2022","journal-title":"J Lipid Res"},{"issue":"12","key":"10.1016\/j.carrev.2025.07.003_bb0260","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","article-title":"Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk","volume":"139","author":"O\u2019Donoghue","year":"2019","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.carrev.2025.07.003_bb0265","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jacc.2019.10.057","article-title":"Effect of alirocumab on lipoprotein(a) and cardiovascular risk after acute coronary syndrome","volume":"75","author":"Bittner","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"37","key":"10.1016\/j.carrev.2025.07.003_bb0270","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.1093\/eurheartj\/ehaa703","article-title":"Differential immunological signature at the culprit site distinguishes acute coronary syndrome with intact from acute coronary syndrome with ruptured fibrous cap: results from the prospective translational OPTICO-ACS study","volume":"41","author":"Leistner","year":"2020","journal-title":"Eur Heart J"}],"container-title":["Cardiovascular Revascularization Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1553838925003550?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1553838925003550?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T04:28:09Z","timestamp":1778819289000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1553838925003550"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":54,"alternative-id":["S1553838925003550"],"URL":"https:\/\/doi.org\/10.1016\/j.carrev.2025.07.003","relation":{},"ISSN":["1553-8389"],"issn-type":[{"value":"1553-8389","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of elevated lipoprotein(a) on epicardial coronary flow conductance and endoluminal atherosclerotic disease distribution","name":"articletitle","label":"Article Title"},{"value":"Cardiovascular Revascularization Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.carrev.2025.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}